title: mTOR Inhibitors in Cancer: What Can We Learn from Exceptional Responses?
authors.affiliation: Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States ; Dana Farber Cancer Institute, Boston, MA 02115, United States ; Broad Institute of MIT and Harvard, Cambridge, MA 02142, United States.
authors.forename: David J
authors.initials: DJ
authors.lastname: Kwiatkowski
authors.affiliation: Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, United States ; Dana Farber Cancer Institute, Boston, MA 02115, United States ; Broad Institute of MIT and Harvard, Cambridge, MA 02142, United States.
authors.forename: Nikhil
authors.initials: N
authors.lastname: Wagle
mesh_terms: D002986:Clinical Trials as Topic; D006801:Humans; D008954:Models, Biological; D009154:Mutation / Q000235:genetics; D009369:Neoplasms / Q000188:drug therapy / Q000201:enzymology*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D015398:Signal Transduction / Q000187:drug effects; D020123:Sirolimus / Q000494:pharmacology / Q000627:therapeutic use; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D047428:Protein Kinase Inhibitors; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus